Of the three highest bidders, Pfizer’s purchase proposal for Metsera was the lowest, regulatory documents reveal. The New ...

Pfizer acquires Metsera to enter the booming obesity drug market with next-gen GLP-1 therapies. Find out why PFE stock is a hold.

The Pfizer stake now accounts for 5.2% of Wilsey’s U.S. equity portfolio, placing it outside the fund’s top five holdings.

Pfizer has re-entered the obesity drug sector by acquiring Metsera, Inc., having successfully outmaneuvered six other bidders ...

The company recently announced an acquisition that will bolster its growth prospects in the GLP-1 obesity market.

President Donald Trump and Pfizer's CEO today announced "TrumpRX" and lower drug prices. But what does Pfizer sell? Here's ...

Pfizer acquired a smaller company for $4.9 billion to improve its prospects in the GLP-1 market. The pharmaceutical giant could carve out a small niche for itself in this growing space. Pfizer's ...

So, a total of $1.9 billion in cost savings, which is modest compared to a market size of $590 billion for pharmaceuticals in ...

Pfizer is getting its hands on a promising weight management candidate. The company's recent deal with the U.S. government ...

One of the most appealing features of Pfizer's stock is its dividend. The payout recently yielded a hefty 7.4% -- and it's been growing over time. There's reason to be bullish over Pfizer's long-term ...

The GLP-1 market has grabbed considerable attention in the past couple of years, and there's little doubt as to which pharmaceutical companies dominate this space. Eli Lilly is currently the leader, ...